is very common, and these has been reported to be a risk factor for arterial and venous thromboses. The study of Leiden thrombophilia established hyperhomocysteinemia (above the 90th percentile) as a risk factor for deep-vein thrombosis. 4 A further metaanalysis showed that a 5 μmol/L elevation in HCY was associated with a 27% higher risk of venous thrombosis in prospective studies and 60% higher risk of venous thrombosis in retrospective studies. Genotype studies of the methylenetetrahydrofolate reductase enzyme showed an association of venous thrombosis with hyperhomocysteinemia. 5 In 1964, McDonald et al 6 concluded that HCY, both in vivo and in vitro, increased platelet stickiness associated with arterial and venous thrombosis, but this finding was not confirmed. [7] [8] [9] In studies of platelet kinetics, a direct relationship was found between HCY concentration and platelet survival. 10 Harker et al 7 found that increased platelet consumption in homocysteinemia was interrupted by dipyridamole, but not by heparin anticoagulation, and concluded that platelet thrombus formation on arterial surfaces denuded of endothelium, and not enhanced platelet reactivity, increased platelet consumption.
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H omocysteine (HCY), a sulfur containing amino acid, is a normal by-product of methionine metabolism. Normal levels of plasma HCY in fasting are considered to be between 5 and 15 μmol/L. Moderate, intermediate, and severe hyperhomocysteinemia refer to concentrations between 16 and 30, between 31 and 100, and >100 μmol/L, respectively. 1 Homocystinuria is consistent with severe hyperhomocysteinemia. Homozygous cystathione β synthetase deficiency, causing homocystinuria, is associated with a thromboembolic event in 30% of patients by the age of 20 years, 50% of patients by the age of 30 years, and 60% of patients by the age of 40 years. 2, 3 Mild and moderately elevated HCY levels (hyperhomocysteinemia)
The mechanism of thrombogenicity in hyperhomocysteinemia remains controversial. The authors investigated the association between elevated plasma homocysteine levels, platelet function, and blood coagulation. Blood was collected from healthy subjects and patients with critical limb ischemia. Basal platelet counts and platelet aggregation as well as flow cytometry were performed to assess spontaneous-and agonist-induced platelet aggregation as well as P-selectin and Glycoprotein IIb/IIIa expression at different homocysteine concentrations. Thromboelastography was performed, and platelet shape change was assessed, using a channelyzer, by measuring median platelet volume. Lactate dehydrogenase was measured, to indirectly assess red blood cell membrane integrity, after homocysteine exposure. The study results suggest that platelet activation and hypercoagulability occur after exposure to homocysteine, especially in patients with critical limb ischemia. Homocysteine concentrations of approximately 50 μmol/L appear to be the level at which these changes occur in vitro, and this effect on platelets appears to be indirect.
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Graeber et al showed that in vitro HCY increased thromboxane A 2 levels compared with control subjects. 11 Enhanced biosynthesis of thromboxane A 2 activates platelets and is associated with several risk factors for vascular disease, including diabetes and hypercholesterolemia. 12 Di Minno et al showed an enhanced thromboxane A 2 biosynthesis in patients with homocystinuria as reflected by the urinary excretion of 11-dehydro thromboxane B 2 (it is the major metabolite). 13, 14 Signorello and colleagues showed that in human platelets, HCY induces the release of arachidonic acid to generate thromboxane A 2 . 15 This finding suggested that the enhanced thromboxane biosynthesis in homozygous homocystinuria 14 is a consequence of increased arachidonate acid mobilization. 15 Thrombosis may result from plaque rupture and platelet activation. Platelet activation leads to the release of proaggregatory factors, which initiate thrombosis. 16, 17 Excessive platelet activity is tightly regulated by endothelial and platelet-derived mediators. However, in patients with elevated HCY, little is known of the exact mechanism predisposing to a hypercoagulable status. Platelets play an important role in the final common pathway for thrombosis and hemostasis; however, the role of platelets in the pathogenesis of HCY-associated thrombosis remains inconclusive. Essentially, the question is whether HCY directly influences platelets or whether the effect is secondary due to action on the endothelium, blood cells, or other factors. We investigated the direct role of HCY on platelet activation in vitro using whole blood platelet aggregation, flow cytometry, and thromboelastography (TEG).
Methods

Patients and Blood Sampling
Young healthy non-smokers who were not taking medication at the time and had not taken medication for 10 days before sampling acted as controls (C). Blood was also collected from patients with critical limb ischemia (CLI) for some experiments. Details of subjects are shown in Table 1 .
Blood samples were collected using a standard technique. Subjects were rested for 15 minutes before blood sampling, using a double-syringe technique with a 21-gauge scalp-vein needle. The first tube was discarded, and blood was collected into 3.8% citrated tubes (9 vol blood, 1 vol citrate). Platelet-rich plasma (PRP) for platelet shape change (PSC) experiments was prepared as previously described 16 and was kept at 37°C to minimize the effect of cooling on platelet function. 18 Platelet studies were completed within 2 hours of collection.
Homocysteine Concentrations
Homocysteine solutions were prepared using normal saline as the diluent (as used for control samples) and added to the samples as described to achieve final concentrations of 0, 10, 20, 50, and 100 μmol/L. These concentrations were chosen to reflect the in vivo concentrations that were observed for mild, moderate, and severe hyperhomocysteinemia. 1 We also used higher (unphysiological) concentrations for the first experiment of aggregation and basal count analysis.
Basal Platelet Counts and Platelet Aggregation
Blood sampling and preparation. Homocysteine was added to whole blood to achieve concentrations of 0, 10, 20, 50, and 100 μmol/L (and higher for basal count analysis), and the samples were incubated at 37°C for 15 minutes.
Equipment. A Coulter Counter
Model T-890 (Coulter Electronics Luton, Bedfordshire, UK) was used for Spontaneous platelet aggregation and basal platelet counts. Aliquots of blood were placed in a plastic cuvette in the Chronolog aggregometer for 10 minutes at 37°C; the basal platelet count was obtained 15 seconds after commencing spinning of the whole citrated blood at 1000 rpm and after the addition of physiological saline (0.9%). Free platelet counts were measured at baseline 1, 3, 6, and 15 minutes after the initiation of spinning. 19 Spontaneous platelet aggregation was assessed for the lower concentrations using the Chronolog aggregometer. For the higher concentrations of HCY, we only measured basal counts, as we found the rate of platelet aggregation extremely rapid; this was also technically easier and allowed quick turnaround of samples.
Agonist-induced platelet aggregation. The basal platelet count was obtained 15 seconds after commencing spinning in the Chronolog aggregometer and before adding agonists. Adenosine diphosphate (final concentration = 5 μmol/L) was added after the basal count and spinning was continued. Platelet counts were assessed at 1, 3, 6, and 15 minutes after the addition of agonist. The process was repeated using 5-hydroxytryptamine (serotonin; final concentration = 10 μmol/L) instead of ADP. The single, free platelet count decreases as a consequence of platelet aggregation. Thus, aggregation is determined by measuring single platelet counts in whole blood before and after stimulation of platelet aggregation. [19] [20] [21] [22] Platelet aggregation can be quantified as the fraction of platelets incorporated into aggregates:
where N o is the platelet count before aggregation and N t , is the platelet count after stimulation of aggregation at time point t.
Flow Cytometric Analysis of Platelet Function
Flow cytometry-monoclonal analysis: 2-color staining technique. Flow cytometry allows the assessment of the activation status of individual platelets by fluorescence activated cell sorting (FACS, Becton Dickinson FACScan, Becton Dickinson UK Ltd, Cowley, Oxford, Oxfordshire, UK), which uses fluorescentlabeled antibodies to detect the expression of activation antigen on the platelet surface. A 2-color technique was used, and 5000 platelets were electronically gated. Monoclonal antibodies were supplied by Becton Dickinson (Beckton Dickinson Immunocytochemistry Systems). CD61 PerCP was used as a platelet specific marker; PAC-1 fluorescein isothiocyanate (FITC) was used to detect the activated glycoprotein (GP) IIb/ IIIa receptor, and CD 62P PE to detect P-selectin expression.
PAC-1 FITC and CD61 PerCP: sample preparation and staining.
Homocysteine was added to citrated whole blood to achieve 0, 10, 20, 50, and 100 μmol/L and incubated at 37°C for 15 minutes. Care was taken to minimize artifactual stimulation of platelets during sample collection and handling. 23 Immediately after sampling, 100 μL of fresh HCY-treated whole blood was added to 20 μL of PAC-1. The samples were maintained for 20 minutes at room temperature (20°C-25°C), in the dark. The PAC-1 FITC samples were then fixed with 1 mL of 1% paraformaldehyde (filtered, pH 7.4) in phosphate-buffered saline with 0.1% azide. The platelets were then washed at 1200g for 5 minutes at room temperature. The supernatant was then aspirated, and the platelet pellet was resuspended in phosphate-buffered saline with 0.1% azide at room temperature. The platelets were then washed (at 1200g for 5 minutes at room temperature). In all, 50 μL of PAC-1 FITC-treated samples was then stained with 20 μL of CD61 PerCP added to each tube and resuspended in phosphate-buffered saline before flow cytometric analysis. Samples were stored at 4°C until analysis.
CD62P PE and CD61 PerCP: sample staining and preparation. Homocysteine was added to whole blood to obtain 0, 10, 20, 50, and 100 μmol/L and incubated at 37°C for 15 minutes. Fresh HCYexposed blood was fixed with the addition of paraformaldehyde and was kept at 4°C in the dark for at least 2 hours. At the end of the 2 hours, each sample was centrifuged at 1200g for 5 minutes at room temperature, and the supernatant was aspirated. Phosphate-buffered saline was added to resuspend the platelet pellet, which was again centrifuged at 1200g for 5 minutes at room temperature. For direct immunofluorescence staining, 20 μL of CD61 and 20 μL of CD62P PE were added to 12 × 75 mm test tubes. A total of 100 μL of fixed platelet suspension was added, and the sample was kept for 20 minutes at room temperature in the dark. The sample was resuspended in phosphate-buffered saline and then centrifuged at 1200g for 5 minutes. Samples were stored at 4°C until analysis.
Instrument setup, data acquisition, and analysis. Data were stored and evaluated using the LYSIS II software (Beckton Dickinson) and offline analysis was performed with WinMDI ver 2.8 software (supplied by Dr J. Trotter, Scripps Inst, La Jolla, California). Activation status was expressed as a percentage, that is percentage of platelets that had specific monoclonal antibody stains in the gated population out of 5000 platelet events in the electronic gate.
Thromboelastography
Thromboelastography is a test for global blood coagulation, from the beginning of clot formation to fibrinolysis; it also evaluates platelet function. 24 Five standard measurements are made on each TEG tracing.
The reaction time R (r) is measured from the start of the tracing to the point where the curve is 1mm wide. The R-value can be expressed in 2 equivalent ways, as the distance in millimeters or as the time in minutes. The R-value is similar to whole blood clotting time. A prolonged R-value is associated with clotting factor deficiencies or anticoagulants such as heparin. Thrombocytopenia may also prolong the R-value.
The coagulation time K (k) is the distance or time from the 1-mm-wide point to the 20-mm-wide point. The K-value is an indication of the rate of increase of elastic shear modulus in the sample and indicates how fast the clot structure forms, and it is abnormal in clotting factor deficiencies, platelet dysfunction, thrombocytopenia, and hypofibrinogenemia.
The α-angle is measured between the midline of the tracing and a line drawn from the 1-mm-wide point tangential to the curve. The α-angle represents the same parameters as the K time.
The maximum amplitude (MA) is the width of the curve at its widest point; it represents the maximum clot elastic shear modulus attainable. This is primarily a function of platelet count and fibrinogen level, that is the structural components of the clot. Thrombocytopenia, hypofibrinogenemia, severe clotting factor deficiencies, or heparin therapy will reduce the maximum amplitude.
Lys/LY30 is a measure of the percentage of clot lysis 30 minutes after MA is reached. Whole blood was added to normal saline at 37°C and gently swirled for control samples. Blood was added to another tube containing HCY (in normal saline) at 50 μmol/L (this represents moderate hyperhomocysteinemia) and gently swirled. Blood was then pipetted into prewarmed cups in the TEG coagulation analyzer (Model 3000C, Haemoscope Corporation, Skobie, Illinois). The instrument was connected to a computer loaded with CTEG analytical software (Haemoscope Corporation). Homocysteine-containing sample was run in parallel with a control (saline) sample.
Platelet Shape Change
Addition of homocysteine and sample fixation. Blood was collected from healthy volunteers as described above. Aliquots of PRP (450 μL) were placed in siliconized glass cuvettes, and HCY was added in 50-μL aliquots to achieve final HCY concentrations of 10, 20, 50, and 100 μmol/L. The sample was incubated at 37°C for 15 minutes and then stirred at 1000 rpm at 37°C. At 0, 5, 10, and 15 minutes after the addition of HCY, 100-μL aliquots of PRP were removed and mixed with 400-μL of fixative (4% vol/vol aqueous glutaraldehyde). All samples were simultaneously run with PRP in saline as controls.
Platelet counting and particle size analysis. Platelet counts were measured in fixed PRP suspensions diluted 400-fold with Isoton II at room temperature. The samples were then processed by a Coulter counter ZM-34 (electrical impedance method, 70 μm diameter sampling tube orifice) coupled to a C-256 channelyzer (Coulter Electronics). 25 The sample "window" was set between 2.67 and 19.12 fL. The counter was calibrated using latex particles of 9 fL vol (Lot 7; Coulter Electronics). For particle analysis, data were accumulated to a maximum of 500 platelets in one of the 256 channels. The median platelet volume (MePV) was the volume of the channel on either side of which 50% of the platelet population was distributed. The median platelet volume rather than mean platelet volume was used, as it was technically easier to quantify accurately. Throughout the study, the platelet count in PRP in each sample was monitored to exclude appreciable platelet aggregation (>5%) that may affect MePV measurements. 26 
Lactate Dehydrogenase and Homocysteine
To investigate whether the free sulfhydryl group of HCY caused injury to the red blood cell membrane (thereby resulting in the leakage of lactate dehydrogenase [LDH] and indirect platelet activation), we added HCY to freshly collected whole blood to achieve concentrations 10, 50, and 100 μmol/L. Normal saline added to whole blood was used as a control sample. All samples were incubated for 15 minutes at 37°C and then centrifuged to separate serum. Any sample that was visibly hemolyzed was discarded. The LDH assay was performed in our hospital laboratory using an enzyme-linked immunosorbent assay technique (LDH Assay Kit, Sigma Chemicals).
Statistical Analysis
Statistical analysis was performed using GraphPad software (GraphPad Software Inc, San Diego, California). A P ≤ .05 was considered significant.
The tests used are mentioned in the relevant results.
Results
Basal Platelet Counts and Aggregation
Basal platelet counts. After the exposure of whole blood (from control patients) to HCY, there was a progressive decrease in the baseline platelet counts 15 seconds after the addition of HCY (P = .048 at 100 μmol/L; P = .019 at 200 μmol/L; Mann-Whitney test). Statistical significance (P < .001) was also achieved for all concentrations above 200 μmol/L (see Figure 1A) .
Platelet aggregation. There were no differences for platelet aggregation in controls after the addition of HCY with spontaneous platelet aggregation ( Figure 1B) , ADP-( Figure 1C ) or 5-HT-induced aggregation ( Figure 1D ; Wilcoxon signed rank test).
Platelet Flow Cytometry
P-selectin, controls. There were no significant intragroup differences for controls (n = 8; Wilcoxon signed rank test) after exposure to HCY at 0, 10, 20, 50, and 100 μmol/L (Figure 2A) . P-selectin, CLI patients. There were no intragroup differences for CLI (n = 12; Wilcoxon Signed rank test) after exposure to HCY at 0, 10, 20, 50, and 100 μmol/L ( Figure 2B) .
P-selectin, comparison of controls and those with
CLI. Comparison of P-selectin expression between the controls (c; n = 8) and those with CLI (n = 12), with flow-cytometric analysis, after exposure to HCY at 0, 10, 20, 50, and 100 μmol/L in each group demonstrated statistical differences between the 2 groups for an HCY concentration of 50 μmol/L, P = .0339 (Mann-Whitney U test; Figure 2A ).
PAC-1 binding, GPIIb/IIIa expression; controls (c).
No significant difference was demonstrated for intragroup comparison after exposure to HCY at different concentrations in controls without vascular disease (n = 8) for HCY at 0, 10, 20, 50, and 100 μmol/L, Wilcoxon signed rank test ( Figure 2B ).
PAC-1 binding, GPIIb/IIIa expression; CLI patients.
Expression of activated platelet membrane GPIIb/IIIa receptor in patients with CLI (n = 12; PAC-1 binding), after exposure to HCY at 0, 10, 20, 50, and 100 μmol/L. Statistical significance was achieved for intragroup comparison of HCY concentration of 20 μmol/L (P = .0322) and for 50 μmol/L (P = .0093), compared with 0 μmol/L, Wilcoxon signed rank test ( Figure 2B ).
PAC-1 binding; comparison of controls (c) and those with CLI.
Comparing activation of platelet membrane GPIIb/IIIa receptor (PAC-1 binding) in controls (c; n = 8) to patients with CLI (n = 12), after exposure to HCY at 0, 10, 20, 50, and 100 μmol/L; Statistical difference was noted for HCY at 50 μmol/L (P = .041; Mann-Whitney test; Figure 2B ).
Thromboelastography
There was a significantly shorter R time (P = .004, Wilcoxon signed rank test) when HCY (50 μmol/L) was added to whole blood from healthy controls (Figure 3 ).
Platelet Shape Change
Platelet-rich plasma prepared from whole blood from healthy controls was exposed to HCY at 10, 20, 50, and 100 μmol/L; each sample was concurrently assessed with an HCY-free control sample. Platelet volume readings were assessed at 0, 5, 10, and 15 minutes. Platelet shape change assessed by platelet volume is a sensitive technique for evaluating platelet activation. No significant changes were found for platelet volume, either for the variables of time or concentration, compared with each other and with the control samples assessed in parallel (Figure 4 ). Mean platelet count was also measured in parallel with platelet volume analysis. No significant difference was noted in platelet counts (Wilcoxon signed rank test).
Lactate Dehydrogenase
No significant differences in LDH activity was observed after 15 minutes exposure to HCY (Wilcoxon signed rank test, results not shown).
Discussion
We demonstrated a dose-dependent early decrease in the basal platelet count after adding HCY. This effect was more pronounced for the unphysiological higher concentrations of HCY used in this study. This suggests that activated platelets were clumping and unavailable for counting. The aggregation experiments exposing platelets to HCY did not demonstrate further significant differences in terms of spontaneous or platelet aggregation induced with ADP or 5 HT. No difference was noted between spontaneous platelet aggregation and ADP-enhanced or 5 HT-enhanced platelet aggregation, suggesting that platelets were already maximally stimulated or that they became less active or exhausted. It may be that superactivated platelets are removed immediately on exposure to HCY as reflected by the fall in basal platelet count. We found no difference for intragroup platelet P-selectin expression at different HCY concentrations for platelets of controls or patients with CLI. Comparison between controls and those with CLI achieved significance at HCY 50 μmol/L (P = .034). This suggests that platelets from patients with CLI had an increased tendency for degranulation. 27 There was no significant intragroup difference for PAC-1 binding in the controls. However, we demonstrated significance for PAC-1 binding in the CLI group for HCY at 20 μmol/L (P = .032) and 50 μmol/L (P = .0093). Comparison of the 2 groups only demonstrated a difference at 50 μmol/L.
Riba et al performed whole blood flow cytometric analysis on platelets in similar experiments; however, no difference in the basal level of fibrinogen binding or P-selectin expression was identified. They also examined P-selectin expression in response to ADP stimulation and demonstrated platelet activation and degranulation in patients with mildly elevated plasma HCY levels. 28 There was a significantly (P = .004) shorter TEG R time at HCY 50 μmol/L in whole blood. A shortened R time, or the time to initial fibrin formation, 29, 30 represents a hypercoagulable state. The mechanism that is responsible remains unclear.
Platelet shape change represents early platelet activation. We were unable to demonstrate any changes in platelet volume at various HCY concentrations. Furthermore, in contrast to the immediate decrease in the platelet count after adding HCY in whole blood, there was no similar decrease in PRP. This suggests that some, as yet unknown, mechanism for platelet activation occurs in whole blood. However, it should be noted that the preparation of PRP might induce platelet activation; but this technique of PSC is extremely sensitive, and the negative result makes a direct action of HCY on platelets less likely. The direct effects of HCY on platelets in whole blood in vitro may be immediate, and although we tried to decrease our time from exposure to analysis, for logistic reasons, we could not decrease our time to less than 10 to 15 minutes (apart from a few experiments) in this study. Lactate dehydrogenase leaks out of red cells in response to membrane damage. Although all the previously described changes occurred after a short exposure to HCY, there was no significant difference in LDH activity after 15 minutes incubation. This experiment also demonstrates that osmotic injury of the red cell membrane was not a consideration at the HCY concentrations studied.
Homocysteine is thought to rapidly autooxidize in plasma to form mixed disulphides and HCY thiolactone. 31, 32 Potent reactive oxygen species are formed during this autooxidation. 33, 34 The superoxide dependent generation of hydroxyl radicals has been reported to initiate lipid peroxidation. 35, 36 Oxidized low-density lipoprotein can induce platelet activation and exert a potent atherogenic effect. 37 Probucol treatment resulted in a 40% to 60% decrease in the excretion of thromboxane metabolite in patients with hyperhomocystinuria but had no effect on 6 healthy subjects. 38 These data suggest that some of the abnormally high platelet thromboxane A 2 production and in vivo platelet activation in patients with hyperhomocysteinemia depend on the mechanisms sensitive to antioxidants. Another study showed that HCY stimulated the release of arachidonic acid to produce thromboxane A 2 and reactive oxygen species accumulation, leading to an unbalanced redox state and human platelet hyperactivity. 15 Homocysteine may induce oxidation of lowdensity lipoprotein in vitro 38 ; because HCY can participate in disulfide-bond exchange reactions, it is possible that excessive HCY can alter plasma proteins (or perhaps red blood cell membranes) by this process. It has been reported that HCY concentrations as low as 8 μmol/L markedly increase the affinity of lipoprotein (a) for plasmin-modified fibrin surfaces, thus inhibiting plasminogen activation. 39 A HCY-induced alteration in platelet metabolism may provide for a release of prothrombotic substances and a possible mechanism for platelet aggregation. Platelet aggregation may then explain intravascular thrombosis, and the platelet-derived promitogenic release substances may also be implicated in the progression of atherosclerotic disease.
Thrombin is a potent platelet activator; Coppola et al investigated the influence of thrombin, in patients with homocystinuria. 40 Increased levels of prothrombin fragment 1 + 2 , thrombin-antithrombin complex, and activated protein C, were observed in patients with homocystinuria on vitamin treatment who were free of vascular disease. However, these abnormalities did not correlate with urinary thromboxane excretion. Protein C levels, but not factor VII or factor II levels, were significantly reduced in patients with homocystinuria and correlated with the degree of hyperhomocysteinemia. Diet-responsive deficiency of factor VII was previously reported in patients who are deficient in cystathione β synthetase. 41 Lentz et al demonstrated a 34% decrease in thrombomodulin anticoagulant activity in the aortas of monkeys with hyperhomocysteinemia. 42 It is generally held that platelet function abnormalities predominate in arterial thrombosis and abnormalities of coagulation and/or fibrinolysis in venous thromboembolism. The reduced protein C levels in hyperhomocysteinemia may be partly responsible for the venous thrombotic manifestations in homozygous homocystinuria. Increased urinary thromboxane excretion was independent of HCY levels and was present both in vitamin B 6 -responsive and nonresponsive patients, and this observation may have an impact on the treatment of hyperhomocysteinemia. 37 In our in vitro experiments, a concentration of HCY of 50 μmol/L was that at which most of the coagulation changes happen. This level of hyperhomocysteinemia in vivo is present in those with homozygous homocystinuria and moderate and severe hyperhomocysteinemia and is consistent with major complications. 43 Endothelial-derived nitric oxide (NO) regulates vessel tone and inhibits platelet activation, adhesion, and aggregation. 44, 45 The initial response of bovine aortic endothelial cells exposed to HCY, after induction of NO synthesis with bradykinin or a calcium ionophore is to increase NO synthesis. 45, 46 Homocysteine reacts with NO to form Snitroso-HCY, 47 which has some of the properties of NO. 48 This represents a protective mechanism against the adverse consequences of elevated HCY. However, high HCY concentrations and prolonged exposure to endothelial cells results in impaired NO production. 44, 48 HCY also reduces NO activity by oxidative degradation 49, 50 and by inhibiting glutathione peroxidase. 35, 46, 51 Homocysteine may cause endothelial injury both by promoting the formation of peroxides and impairing their inactivation. Stampfer et al reported potential antagonism between NO-related function and HCY. 48 Loscalzo regarded this antagonism as resulting from an effect of chronic exposure to elevated HCY on the production of NO, which leads to unopposed HCY-mediated oxidative endothelial injury. 35 Riba et al demonstrated that platelet sensitivity to NO in the presence of hyperhomocysteinemia is significantly diminished and concluded that this involved a direct effect of HCY on platelets. 28 In contrast, using the techniques described in this study, no direct platelet activation was observed for HCY, suggesting that the influence of HCY on platelet activation is secondary. One exciting area for future work would be to prestimulate the platelets with a low concentration of an agonist and determine whether HCY enhances platelet activation.
In conclusion, our findings suggest that platelet activation and hypercoagulability occur after exposure to HCY, especially in patients with CLI. Homocysteine concentrations of around 50 μmol/L appear to be the level at which these changes occur in vitro. Homocysteine may not directly activate platelets, and this effect of HCY (platelet activation) is not mediated by red cell membrane injury.
